Moffitt begins 2013 with two new programs, Cancer Biology & Evolution and Chemical Biology & Molecular Medicine.
Over the last few years, the Molecular Oncology & Drug Discovery (MODD) Program developed an increasing emphasis on research in the areas of tumor evolution, the microenvironment, mathematical modeling and tumor ecology. The Center’s mathematicians have played an important role in leading this new direction. At the same time, breakthroughs in genomics and personalized medicine led to the structural biologists and chemists in the program to increasingly work closely with members of the Experimental Therapeutics program on drug development and on systems level views of pathways and drugs. Due to these evolving interests, the time came to reorganize these two programs around these new themes. Therefore, the MODD Program has evolved into the Cancer Biology & Evolution Program and the Experimental Therapeutics Program has evolved into the Chemical Biology & Molecular Medicine Program.
The initial goal of the Chemical Biology & Molecular Medicine Program (CBMM) is to integrate chemical biology, genomics, and molecular imaging to develop new therapeutic approaches for cancer. Initially, the program aims to:
- Identify, validate and characterize molecular targets and actionable deregulated pathways with therapeutic relevance in subsets of human cancer.
- Design small molecule chemical probes to modulate such molecular targets and deregulated pathways.
- Identify novel biomarker strategies using proteomics, genomics and molecular imaging to guide clinical decision making.
- Develop and implement mechanism-based therapeutic clinical trials.
Eric B. Haura, MD
Saïd Sebti, PhD